MitoRestore Pharmaceuticals is a clinical-stage biotechnology company focused on developing mitophagy-inducing therapeutics for neurodegenerative diseases, with an initial focus on Parkinson's disease. Founded in 2020 and headquartered in San Diego, California, MitoRestore is pioneering approaches to restore the cellular mitophagy pathway that is defective in most forms of PD["@mitorestore"].
...
Overview
Mermaid diagram (expand to render)
MitoRestore Pharmaceuticals is a clinical-stage biotechnology company focused on developing mitophagy-inducing therapeutics for neurodegenerative diseases, with an initial focus on Parkinson's disease. Founded in 2020 and headquartered in San Diego, California, MitoRestore is pioneering approaches to restore the cellular mitophagy pathway that is defective in most forms of PD["@mitorestore"].
The company's lead program, MR-201, is a small molecule PINK1 activator designed to restore mitophagy—the cellular process that clears damaged mitochondria—directly addressing one of the fundamental pathogenic mechanisms in Parkinson's disease.
Scientific Rationale
Mitophagy Defects in Parkinson's Disease
The mitophagy pathway is critically impaired in Parkinson's disease:
PINK1 mutations: Loss-of-function mutations cause familial PD through mitophagy disruption
Parkin dysfunction: Impaired recruitment of Parkin to damaged mitochondria
Dopaminergic vulnerability: Substantia nigra neurons are particularly dependent on mitophagy
Alpha-synuclein intersection: Aggregated alpha-synuclein interferes with mitophagy
MR-201 Mechanism of Action
MR-201 is a first-in-class PINK1 activator that works through multiple mechanisms:
PINK1 stabilization: Prevents degradation of PINK1 on the outer mitochondrial membrane
Parkin recruitment: Facilitates Parkin recruitment to damaged mitochondria
Phosphoubiquitin generation: Promotes generation of phospho-ubiquitin chains
Autophagosome formation: Enhances clearance of damaged mitochondria
Pipeline Overview
| Drug | Mechanism | Indication | Phase | Status | |------|-----------|------------|-------|--------| | MR-201 | PINK1 activator | Parkinson's Disease | Phase 1 | Active | | MR-301 | Autophagy enhancer | PD with GBA mutations | Preclinical | IND-enabling | | MR-401 | Mitochondrial biogenesis | Age-related neurodegeneration | Discovery | Research |
Clinical Development
MR-201 Phase 1 Program
Phase 1a (2024): First-in-human study in healthy volunteers demonstrated safety and target engagement. The study measured:
PINK1 levels in peripheral blood mononuclear cells
[Mitochondrial](/mechanisms/mitochondrial-dysfunction) function biomarkers
Pharmacokinetic profile
Phase 1b (2025): Multiple dose study in early PD patients (Hoehn & Yahr stages 1-3) is evaluating:
Safety and tolerability over 28 days
Biomarkers of mitophagy activation
Motor function (MDS-UPDRS parts II and III)
Non-motor symptoms (MoCA,嗅觉 tests)
Clinical Trial Details
| Parameter | Value | |-----------|-------| | Design | Randomized, double-blind, placebo-controlled | | Patients | Early PD (n=36) | | Dose groups | 25mg, 50mg, 100mg | | Duration | 28 days treatment |
Preclinical Data
PINK1 Drosophila Model
In Drosophila with PINK1 loss-of-function mutations, MR-201:
Restored mitochondrial morphology in dopaminergic neurons
Aging model: Improved mitophagy markers in substantia nigra
Biomarker Studies
Increased Parkin recruitment to mitochondria
Elevated LC3-II/LC3-I ratio in neurons
Reduced mitochondrial ROS
Improved ATP/ADP ratio
Corporate Information
| Attribute | Details | |-----------|---------| | Headquarters | San Diego, California, USA | | Founded | 2020 | | CEO | Dr. Michael Torres | | CSO | Dr. Jennifer Nakamura | | Funding | Series A ($25M, 2021), Series B ($55M, 2024) | | Investors | OrbiMed, RA Capital, MPM Capital |
Research Collaborations
MitoRestore maintains partnerships with leading research institutions: